系统性硬化症相关间质性肺疾病患者继续接受尼达尼布治疗:SENSCIS-ON 数据
SENSCIS-ON 开放标签扩展试验评估尼达尼布治疗系统性硬化症相关间质性肺疾病(SSc-ILD)52 周的安全性和用力肺活量(FVC)变化;继续尼达尼布组 197 例与始用尼达尼布组 247 例,腹泻发生率分别为 68.0% 和 68.8%,不良事件导致停药分别为 4.6% 和 21.5%;FVC 自基线至第 52 周平均(SE)变化分别为 -58.3(15.5)mL 和 -44.0(16.2)mL;结论为安全性与 SENSCIS 一致,FVC 变化与 SENSCIS 尼达尼布组相似。
要点
- SENSCIS-ON 中继续尼达尼布组 197 例,始用尼达尼布组 247 例。
- 腹泻发生率继续组 68.0%,始用组 68.8%。
- 不良事件导致停药继续组 4.6%,始用组 21.5%。
核心结论
- SENSCIS-ON 中尼达尼布 52 周的安全性特征与 SENSCIS 报告的一致。
- SENSCIS-ON 中 52 周内 FVC 变化与 SENSCIS 尼达尼布组观察到的相似。
研究设计与样本
- SENSCIS-ON 为开放标签扩展试验,评估更长期尼达尼布治疗的安全性和 FVC 下降。
- 完成 SENSCIS 试验或尼达尼布与口服避孕药药物相互作用(DDI)研究且正在治疗的患者符合进入 SENSCIS-ON 的条件。
- 在 SENSCIS 中接受尼达尼布并在 SENSCIS-ON 中继续尼达尼布的患者为继续尼达尼布组,共 197 例。
- 在 SENSCIS 中接受安慰剂并在 SENSCIS-ON 中开始尼达尼布、或在 DDI 研究中接受尼达尼布 ≤28 天的患者为始用尼达尼布组,共 247 例。
- 评估 SENSCIS-ON 52 周内不良事件和 FVC 变化。
主要发现
- 继续尼达尼布组腹泻报告率为 68.0%,始用尼达尼布组为 68.8%。
- 不良事件导致尼达尼布停药在继续尼达尼布组为 4.6%,在始用尼达尼布组为 21.5%。
- FVC 自基线至 SENSCIS-ON 第 52 周的平均(SE)变化在继续尼达尼布组为 -58.3(15.5)mL,在始用尼达尼布组为 -44.0(16.2)mL。
关键数值与推荐
- 继续尼达尼布组 197 例,始用尼达尼布组 247 例。
- 腹泻:继续尼达尼布组 68.0%,始用尼达尼布组 68.8%。
- 不良事件导致停药:继续尼达尼布组 4.6%,始用尼达尼布组 21.5%。
- FVC 第 52 周平均(SE)变化:继续尼达尼布组 -58.3(15.5)mL,始用尼达尼布组 -44.0(16.2)mL。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) versus placebo, with adverse events that were manageable for most patients. An open-label extension trial, SENSCIS-ON, is assessing safety and FVC decline during longer term nintedanib treatment. METHODS: Patients who completed the SENSCIS trial or a drug-drug interaction (DDI) study of nintedanib and oral contraceptive on treatment were eligible to enter SENSCIS-ON. Adverse events and changes in FVC over 52 weeks of SENSCIS-ON were assessed in patients who received nintedanib in SENSCIS and continued nintedanib in SENSCIS-ON ('continued nintedanib' group) and in patients who received placebo in SENSCIS and initiated nintedanib in SENSCIS-ON or who received nintedanib for ≤28 days in the DDI study ('initiated nintedanib' group). RESULTS: There were 197 patients in the continued nintedanib group and 247 in the initiated nintedanib group. Diarrhoea was reported in 68.0% and 68.8% of patients in these groups, respectively. Adverse events led to discontinuation of nintedanib in 4.6% and 21.5% of the continued nintedanib and initiated nintedanib groups, respectively. Mean (SE) changes in FVC from baseline to week 52 of SENSCIS-ON were -58.3 (15.5) mL in the continued nintedanib group and -44.0 (16.2) mL in the initiated nintedanib group. CONCLUSIONS: The safety profile of nintedanib over 52 weeks of SENSCIS-ON was consistent with that reported in SENSCIS. The change in FVC over 52 weeks of SENSCIS-ON was similar to that observed in the nintedanib group of SENSCIS.
引用
- Allanore Y, Vonk MC, Distler O, et al. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis. 2022. PMID: 35973804. doi:10.1136/ard-2022-222564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。